Featured Research

from universities, journals, and other organizations

MicroRNA panel provides a more precise lung cancer diagnosis

Date:
October 1, 2010
Source:
American Association for Cancer Research
Summary:
A test based on a panel of microRNAs under development in Israel may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

Tina B. Edmonston, M.D., director of the clinical laboratory at Rosetta Genomics, Inc., presented data on the assay at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, held here.

Lung cancers are traditionally divided into two main groups, either neuroendocrine or non-small cell lung cancer. In 20 to 30 percent of the cases it is difficult to make a definitive diagnosis of the tumor subtype using fine needle biopsy.

"Subclassification has become very important in the determination of patient management," said Edmonston. "This subclassification leads to treatment decisions, so it is very important to make the diagnosis accurately."

Using their proprietary assay, which is still under development, Edmonston and colleagues were able to further subclassify non-small cell lung cancer into squamous and non-squamous, and neuroendocrine into small cell lung cancer and carcinoid with a high level of sensitivity and specificity.

Edmonston said this assay would result in better treatment decisions because not all subtypes of lung cancer will respond to certain drugs and some may even pose unique risks.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "MicroRNA panel provides a more precise lung cancer diagnosis." ScienceDaily. ScienceDaily, 1 October 2010. <www.sciencedaily.com/releases/2010/09/100929163409.htm>.
American Association for Cancer Research. (2010, October 1). MicroRNA panel provides a more precise lung cancer diagnosis. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/09/100929163409.htm
American Association for Cancer Research. "MicroRNA panel provides a more precise lung cancer diagnosis." ScienceDaily. www.sciencedaily.com/releases/2010/09/100929163409.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins